Document Detail


Non-anaesthesiologists should not be allowed to administer propofol for procedural sedation: a Consensus Statement of 21 European National Societies of Anaesthesia.
MedLine Citation:
PMID:  21705907     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Propofol, which is the most commonly used drug for induction of general anaesthesia, has also become a popular drug for procedural sedation. Because its use may be associated with serious and potentially fatal side-effects, the manufacturers of propofol restrict its use solely to personnel trained in general anaesthesia. In spite of this warning, the use of propofol for procedural sedation by non-anaesthesiologists is rapidly expanding in many countries. Recently, the US Food and Drugs Administration (FDA) denied a petition from gastroenterologists seeking the removal of this particular restriction. This unequivocal ruling of the FDA received strong support from the American Society of Anesthesiologists (ASA). At about the same time, the European Society of Anaesthesiology (ESA), together with various European gastroenterology societies, published new guidelines entitled 'Non-anaesthesiologist Administration of Propofol for Gastrointestinal Endoscopy' (NAAP). Following publication of the NAAP guidelines, many reservations have been expressed by ESA member societies and individuals, dealing with professional, political, procedural and safety-oriented concerns. Out of concern for patient safety, and in order to officially and publicly dissociate themselves from the NAAP guidelines, 21 national societies of anaesthesiology in Europe, all of whom are ESA members, have signed a Consensus Statement confirming that due to its significant well known risks, propofol should be administered only by those trained in the administration of general anaesthesia.
Authors:
Azriel Perel
Related Documents :
1688297 - Neurological and neuropsychological complications of hiv infection, monterey, californi...
19830617 - A transnational conference romance: elsie andrews, hildegarde kneeland, and the pan-pac...
20165257 - David alter and other spectroscopists in western pennsylvania.
20432187 - Superbugs and superdrugs-smi's 12th annual conference--overcoming resistance. 17-18 mar...
19597967 - Mobile-centric ambient intelligence in health- and homecare-anticipating ethical and le...
20499187 - Designing rites to re-enchant secularized society: new varieties of spiritualized thera...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of anaesthesiology     Volume:  28     ISSN:  1365-2346     ISO Abbreviation:  Eur J Anaesthesiol     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-08     Completed Date:  2011-10-27     Revised Date:  2012-03-22    
Medline Journal Info:
Nlm Unique ID:  8411711     Medline TA:  Eur J Anaesthesiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  580-4     Citation Subset:  IM    
Affiliation:
Department of Anaesthesiology and Intensive Care, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel. perelao@shani.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anesthesiology / methods
Conscious Sedation / adverse effects,  methods*
Consensus
Endoscopy, Gastrointestinal / methods
Europe
Humans
Hypnotics and Sedatives / administration & dosage*,  adverse effects
Practice Guidelines as Topic
Propofol / administration & dosage*,  adverse effects
Societies, Medical
Chemical
Reg. No./Substance:
0/Hypnotics and Sedatives; 2078-54-8/Propofol
Comments/Corrections
Comment In:
Eur J Anaesthesiol. 2011 Aug;28(8):553-5   [PMID:  21734505 ]
Eur J Anaesthesiol. 2012 Jan;29(1):50-1   [PMID:  21885978 ]
Eur J Anaesthesiol. 2012 Jan;29(1):51-2   [PMID:  22089515 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Association Between Blood Pressure and Incident Alzheimer Disease: A Systematic Review and Meta-...
Next Document:  Nutritional epidemiological studies in cancer prevention: what went wrong, and how to move forwards.